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fn a recent prospective, double-blind, randomized
multicenter phase 3 trial, ADVANCE (Adeno-
sine versus Regadenoson Comparative Evalua-
tion for Myocardial Perfusion Imaging), the A2A
elective adenosine receptor agonist, regadenoson,
as shown to be noninferior to the nonselective
asodilator, adenosine, for detecting myocardial
schemia (1). The overall visual agreement was
omparably low (in the low 60% range) for the
denosine–regadenoson and for the adenosine–
denosine comparisons. Conversely, when quanti-
ative analysis was applied, regadenoson induced
irtually identical results to adenosine–regarding
he size and severity of left ventricular perfusion
efect size and extent of ischemia (2). What are
he regulatory implications of these findings?
hould the regulatory bodies rely on subjective vi-
ual interpretation of myocardial perfusion studies,
n objective quantitative programs to appraise the
omparability between vasodilators, or both?
hat is the “true” standard?
In order to avoid the inherent biological vari-
bility of reimaging a subject twice, Food and
rug Administration (FDA) clinical trials usually
eep the minimal time interval between serial
tudies, and maintain the same medical regimen
nd image acquisition parameters. For example, if
he clinical trial is comparing 2 vasodilators, such
s regadenoson and adenosine, then the investiga-
ors would apply the same radiotracer, camera,
nd image acquisition protocol for the 2 serial
maging studies. On the other hand, if the com-
arison is between 2 radiotracers, then the inves-
igators would apply the same stressor, exercise, or
asodilator, for the 2 serial imaging studies.d
rom the *University of Maryland School of Medicine, Baltimore,
aryland; and the †University of California-Irvine, Irvine, California.hen it comes to the interpretation of the re-
ional perfusion defects, there are 2 options: 1)
isual interpretation, where 2 or more blinded ex-
ert readers apply a pre-defined semiquantitative
coring system; or 2) an automated quantitative
nalysis using a previously validated software that
mploys a sex-specific normal database.
Currently, the regulatory agencies favor visual
nterpretation of images by expert readers. Be-
ause visual interpretation is the standard for in-
erpreting myocardial perfusion studies in clinical
ractice, the regulatory body would like to mimic
he “real-world” application as close as possible.
isual analysis entails reviewing the raw stress
nd rest cardiac images as well as reconstructed
nd normalized paired tomographic images to
dentify all sorts of extracardiac and motion arti-
acts. Segmental scores are assigned, using a 17-
egment model, to generate size and severity of
erfusion defects on stress (summed stress score)
nd extent of reversibility when compared to rest
mages (summed difference score). While the
linded readers may all agree on the final inter-
retation of the images, which essentially reflects
he impression of a clinical report, there may be
ignificant variability in the visual scoring of the
natomical extent, severity, and reversibility of the
erfusion defects among the blinded readers. The
atter has been ascribed as the human variability
omponent (3). Thus, when it comes to visual
nterpretation and scoring, is “the devil in the
etails”?
Because of the inherently digital nature of radi-
nuclide imaging, it lends itself well to an objec-
ive quantitative analysis. Quantitative programs
re highly reproducible and may be better suited
or assessing serial studies and/or for identifying
ifferences in defect size and reversibility. On the
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1038ther hand, there are several automated software
rograms that use different methodology for
uantification, and the data are not necessarily in-
erchangeable. Unlike visual assessment, auto-
ated programs cannot differentiate artifactual
efects (e.g., patient motion or subdiaphragmatic
isceral activity) from true perfusion defects.
Since quantitative programs are almost univer-
ally available on all nuclear cameras, perhaps the
est approach is to go “hybrid.” That is, use the
dvantages of visual and quantitative analysis in
ombination in order to optimize the data to be
losest to the “truth.” One of the key advantages
f visual imaging is to differentiate true regional
erfusion defects from artifacts. In contrast, an
mportant advantage of automated analysis is to
bjectively quantify the presence, extent, and se-
erity of myocardial perfusion defects. From a
egulatory perspective, perhaps the blinded readers
hould review the stress and rest image set for
uality of acquisition and artifacts. If the images
ass the visual inspection or pass after minor
odification, e.g., reslicing the images or usingobesity, and diabetes on the efficacy comparable left venenerated by the automated quantitative program
n all 17 segments. On the other hand, if there
re extracardiac activities, e.g., bowel activity
djacent to or overlying the inferior region that
annot be corrected, then the images will be in-
erpreted and scored visually. Such a hybrid ap-
roach should minimize noise incurred by seg-
ental human scoring while taking into
onsideration extracardiac artifacts that often go
ndetected or identified spuriously abnormal by
utomated programs.
At the present time, the role of a fully auto-
ated quantitative analysis, with or without visual
nterpretation, for a new imaging agent or vasodi-
ator is not clearly defined in FDA guidance doc-
ments. Perhaps it is time for the best of both
orlds!
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